Comparison of Serum Visfatin Levels in Post-Menopausal Pakistani Women with and Without Breast Carcinoma

Lubna Gohar; Umbreen Ahmed; Nadeem  Zafar; Mansoor Wahid; Shoaib bin Aleem; Shazia Junaid

doi:10.51253/pafmj.v73i6.6929

Authors

Lubna Gohar Department of Physiology, Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Umbreen Ahmed Department of Physiology, Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Nadeem Zafar Department of Histopathology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Mansoor Wahid Department of Oncology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Shoaib bin Aleem Department of Physiology, Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Shazia Junaid Department of Physiology, Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v73i6.6929

Keywords:

Breast Carcinoma, Menopause, Obesity, Visfatin

Abstract

Objective: To compare serum Visfatin levels in Pakistani post-menopausal women having breast carcinoma with healthy
women.

Study Design: Comparative cross-sectional study.

Place and Duration of Study: Physiology Department, Army Medical College, in collaboration with Armed Forces Institute of Pathology, Rawalpindi, Pakistan, from Dec 2019 to Dec 2020.

Methodology: Eighty post-menopausal Pakistani women were included, out of which forty women were post-menopausal
newly diagnosed and histologically confirmed cases of breast carcinoma awaiting their treatment. Menopause was confirmed through interviews and relevant history. Serum Visfatin levels were determined using an enzyme-linked immunosorbent assay (ELISA).

Result: Mean serum Visfatin levels were significantly higher in the Breast Carcinoma-Group (28.14±8.17 ng/ml) compared to the Healthy Control-Group (13.64±1.07 ng/ml). Moreover, serum Visfatin levels correlated positively with weight (r=0.735), body mass index (r=0.678), waist circumference(r=0.295) and waist-to-hip ratio (r=0.220).

Conclusion: Serum Visfatin levels were markedly elevated in post-menopausal women with breast carcinoma as compared toHealthy Controls. Higher serum Visfatin may be regarded as a potential risk factor in the development of breast carcinoma.